Details

Autor(en) / Beteiligte

• Pham, Van Luan
• Le, Tuan Anh
• Pham, Cam Phuong
• Hoa Nguyen, Thi Thai
• Do, Anh Tu
• Nguyen, Tuan Khoi
• Nguyen, Minh Hai
• Thu Hoang, Thi Anh
• Hao Vuong, Dinh Thy
• Tam Nguyen, Dac Nhan
• Khiem Dang, Van
• Nguyen, Thi Oanh
• Trang Vo, Thi Huyen
• Do, Hung Kien
• Vu, Ha Thanh
• Nguyen, Thi Thuy Hang
• Pham, Van Thai
• Trinh, Le Huy
• Dung Nguyen, Khac
• Nguyen, Hoang Gia
• Truong, Cong Minh
• Chau Pham, Tran Minh
• Nguyen, Thi Bich Phuong

Titel

Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam

Ist Teil von

• Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241242972-17588359241242972

Ort / Verlag

England: SAGE Publishing

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Afatinib is indicated for advanced-stage non-small-cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) and uncommon mutations. However, real-world studies on this topic are limited. This study aimed to evaluate afatinib as first-line therapy for locally advanced and metastatic NSCLC with uncommon EGFR mutations. A retrospective study included 92 patients with advanced NSCLC with uncommon and compound EGFR mutations, treated with afatinib as first-line therapy. Patients were followed up and evaluated every 3 months or when symptoms of progressive disease arose. The endpoints were objective response rate (ORR), time-to-treatment failure (TTF), and adverse events. The G719X EGFR mutation had the highest occurrence rate (53.3% for both monotherapy and the compound). By contrast, the compound mutation G719X-S768I was observed at a rate of 22.8%. The ORR was 75%, with 15.2% of patients achieving complete response. The overall median TTF was 13.8 months. Patients with the G719X EGFR mutation (single and compound) had a median TTF of 19.3 months, longer than that of patients with other mutations, who had a median TTF of 11.2 months. Patients with compound EGFR mutations (G719X and S768I) demonstrated a median TTF of 23.2 months compared to that of 12.3 months for other mutations. Tolerated doses of 20 or 30 mg achieved a longer median TTF of 17.1 months compared to 11.2 months with 40 mg. Median TTF differed between patients with and without brain metastasis, at 11.2 and 16.9 months, respectively. Rash (55.4%) and diarrhea (53.3%) were the most common adverse events, primarily grades 1 and 2. Other side effects occurred at a low rate. Afatinib is effective for locally advanced metastatic NSCLC with uncommon EGFR mutations. Patients with G719X, compound G719X-S768I mutations, and tolerated doses of 20 or 30 mg had a longer median TTF than those with other mutations.